PMID- 36869780 OWN - NLM STAT- MEDLINE DCOM- 20230330 LR - 20230619 IS - 1096-9071 (Electronic) IS - 0146-6615 (Linking) VI - 95 IP - 3 DP - 2023 Mar TI - Poor glycemic control in type-2 diabetic patients infected with hepatitis B: A retrospective propensity-matched study. PG - e28635 LID - 10.1002/jmv.28635 [doi] AB - Hepatitis B virus (HBV) infection and type-2 diabetes mellitus (T2DM) affect millions of individuals worldwide, whereas their interplay remains largely unclear. Here, we analyzed a large cohort of 330 HBV-infected inpatients with T2DM (so-called HBV + T2DM patients) and 330 T2DM inpatients without HBV infection (T2DM patients). Poor glycemic control was defined by glycated hemoglobin (HbA1c) >/= 7%. Among 330 HBV + T2DM patients, 252 (76%) aged >/= 50 years, 223 (68%) were males, 205 (62%) experienced poor glycemic control. The propensity-score matching approach was applied to match patient age, gender, comorbidities, and antidiabetic treatment between T2DM + HBV and T2DM patients. Compared with T2DM patients, HBV + T2DM patients had poorer glycemic control, longer hospitalization length, and higher alanine aminotransferase (p < 0.05). HBV + T2DM patients with HBV DNA >/= 100 IU/mL or HBsAg >/= 0.05 IU/mL had worse HbA1c control than T2DM patients without HBV infection (p < 0.05). HBV + T2DM patients who received no anti-HBV therapy had worse HbA1c control than HBV + T2DM patients receiving anti-HBV therapy (p < 0.05). Both insulin and anti-HBV therapy were significant factors associated with glycemic control in HBV + T2DM patients. Overall, HBV + T2DM patients exhibited poorer glycemic control than T2DM patients, but their clinical outcomes were likely improved by insulin plus anti-HBV treatment. Early management of HBV infection likely contributes to better clinical outcomes in HBV-infected patients with T2DM. CI - (c) 2023 Wiley Periodicals LLC. FAU - Cai, Ting AU - Cai T AD - Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China. AD - Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, China. FAU - Yue, Tingting AU - Yue T AD - Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China. FAU - Xu, Ming AU - Xu M AD - Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China. FAU - Zhang, Pan AU - Zhang P AD - Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China. FAU - Wang, Yue AU - Wang Y AD - Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China. FAU - Liu, Qi AU - Liu Q AD - Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China. FAU - Huang, Jie AU - Huang J AD - Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China. FAU - Shen, Ting AU - Shen T AD - Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, China. FAU - Yin, Qiang AU - Yin Q AD - Hunan Children's Hospital, Changsha, China. FAU - Sheng, Zhifeng AU - Sheng Z AD - Key Laboratory of Diabetes Immunology, Hunan Key Laboratory for Metabolic Bone Diseases, Department of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, Ministry of Education, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Xiao, Yang AU - Xiao Y AD - Key Laboratory of Diabetes Immunology, Hunan Key Laboratory for Metabolic Bone Diseases, Department of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, Ministry of Education, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Deng, Tuo AU - Deng T AD - Key Laboratory of Diabetes Immunology, Hunan Key Laboratory for Metabolic Bone Diseases, Department of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, Ministry of Education, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Zhang, Min AU - Zhang M AD - Institute of Hepatology and Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - De Clercq, Erik AU - De Clercq E AD - Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. FAU - Zhang, Chi AU - Zhang C AD - Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, China. FAU - Li, Guangdi AU - Li G AUID- ORCID: 0000-0001-8852-034X AD - Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China. AD - Hunan Children's Hospital, Changsha, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Med Virol JT - Journal of medical virology JID - 7705876 RN - 0 (Glycated Hemoglobin) RN - 0 (Blood Glucose) RN - 0 (Insulin) SB - IM MH - Male MH - Humans MH - Female MH - Retrospective Studies MH - Glycated Hemoglobin MH - Glycemic Control MH - Blood Glucose MH - *Diabetes Mellitus, Type 2/complications/drug therapy MH - *Hepatitis B/complications/drug therapy MH - Insulin/therapeutic use MH - Hepatitis B virus/genetics OTO - NOTNLM OT - Glycemic control OT - HBV OT - Hemoglobin A1c OT - Propensity score matching OT - Type 2 diabetes EDAT- 2023/03/05 06:00 MHDA- 2023/03/30 06:11 CRDT- 2023/03/04 07:32 PHST- 2023/02/27 00:00 [revised] PHST- 2022/10/18 00:00 [received] PHST- 2023/03/01 00:00 [accepted] PHST- 2023/03/30 06:11 [medline] PHST- 2023/03/05 06:00 [pubmed] PHST- 2023/03/04 07:32 [entrez] AID - 10.1002/jmv.28635 [doi] PST - ppublish SO - J Med Virol. 2023 Mar;95(3):e28635. doi: 10.1002/jmv.28635.